PubMed Health⌕ Search

Biomedical subjects

H Emilsson

Publications and source records attributed to H Emilsson.

11 recordsLinked to original sources
PubMed1988

High-performance liquid chromatographic determination of cadralazine in human plasma and urine.

A sensitive and selective high-performance liquid chromatographic method for determination of intact cadralazine in human plasma or urine has been developed. The sample was buffered (plasma, pH 7.6; urine, pH 12.0) and mixed with internal standard before it was applied to an Extrelut-3 column. After adsorption, the column was eluted with chloroform, and the eluate was extracted with sodium acetate-hydrochloric acid buffer (pH 2.1). A 20-microliters aliquot of the aqueous phase was chromatographed on a 5-microns Spherisorb ODS reversed-phase column, with acetonitrile-phosphate buffer (pH 6.0, 25:75) as eluent. The quantitation was achieved by monitoring the ultraviolet absorbance at 254 nm. The detection limit was 0.03 nmol/ml in plasma and 5.00 nmol/ml in urine. The within-assay variation and the day-to-day reproducibility were less than or equal to 10% for plasma or urine standard samples. No interferences from possible metabolites or endogenous constituents could be noted. The utility of the method was demonstrated by analysing cadralazine in samples from one hypertensive subject on a therapeutic dose of the drug (7.5 mg orally).

Antihypertensive Agents↗
PubMed1987

High-performance liquid chromatographic determination of glipizide in human plasma and urine.

A sensitive and selective high-performance liquid chromatographic method for determination of intact glipizide in human plasma or urine has been developed. The plasma and urine samples were acid-buffered, before tolbutamide was added as internal standard. The samples were extracted with benzene, and the organic layer was evaporated to dryness. The residue was dissolved in equilibrated mobile phase (acetonitrile-0.01 M phosphate buffer pH 3.5, 35:65), and an aliquot of 20 microliters was chromatographed on a Spherisorb ODS reversed-phase column. Quantitation was achieved by monitoring the ultraviolet absorbance at 275 nm. The response was linear (0-1000 ng/ml) and the detection limit was 5-10 ng/ml in plasma or urine. The within-assay variation was less than or equal to 10%. No interferences from metabolites or endogenous constituents were observed. The utility of the assay was demonstrated by determining glipizide in samples from a diabetic subject receiving a therapeutic dose of 5 mg of the drug.

Chromatography, High Pressure Liquid↗
PubMed1986

High-performance liquid chromatographic determination of glibenclamide in human plasma and urine.

A selective and sensitive high-performance liquid chromatographic method for determination of intact glibenclamide in human plasma or urine has been developed. With glibornuride as internal standard, acid-buffered plasma or urine was extracted with benzene. The organic layer was evaporated and the residue was dissolved in equilibrated mobile phase (acetonitrile-phosphate buffer 0.01 M pH 3.5, 50:50). An aliquot of 20 microliters was chromatographed on a Spherisorb ODS reversed-phase column, and quantitation was achieved by monitoring the ultraviolet absorbance at 225 nm. The response was linear (0-1000 ng/ml) and the detection limit was 5-10 ng/ml in plasma or urine. The within-assay variation was less than or equal to 10%. No interferences from metabolites or endogenous constituents could be noted. The utility of the method was demonstrated by analysing glibenclamide in samples from diabetic subjects on therapeutic doses of the drug.

Chromatography, High Pressure Liquid↗
PubMed1985

Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects.

The kinetics and dynamics of total and free (unbound) disopyramide (D) after dosing with D, 1.5 and 2 mg/kg iv, were compared with those of the dealkylated metabolite (MND) after dosing with MND, 0.5 and 1.5 mg/kg iv, in six healthy subjects. Dynamic parameters included ECG with measurement of the QT interval corrected for heart rate (QTc), systolic time intervals, vitamin C-stimulated saliva secretion, pupil size, and maximum accommodation capacity. Mean values of total clearance, apparent volume of distribution, and elimination t1/2 of MND were 5.9, 2.3, and 0.4 times those of total D, respectively. D significantly prolonged the QTc and systolic time intervals and induced transient inhibition of stimulated saliva secretion. In contrast, MND induced no substantial change in either the QTc or systolic time intervals, but did induce more persistent inhibition of salivary secretion. If anticholinergic potency is determined as the degree of inhibition of stimulated saliva flow per plasma concentration unit, MND was three times as potent as its parent when measured at maximum inhibition. There were no consistent drug effects on the ocular parameters. The effect of D on QTc correlated with both total and free plasma concentrations. Furthermore, its transient salivary inhibitory effect paralleled its initial rapid decline in plasma concentration. There was no relationship between the MND plasma concentration and its salivary inhibitory effect. We conclude that disopyramide significantly affected the QTc and systolic time intervals in healthy subjects, while MND in a similar dose had no such effects. MND more strongly inhibited stimulated saliva flow, indicating a more potent anticholinergic effect than D.

Adult↗
PubMedDate not supplied

Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.

Eight patients aged 57-86 years with non-insulin-dependent diabetes mellitus (NIDDM) taking long-term glibenclamide treatment (5-15 mg/day) were given oral trimethoprim-sulphamethoxazole due to an acute bacterial infection. After 4-6 days of combined treatment, the total plasma glibenclamide concentrations were determined every second hour for 12 h, and the area under the curve (AUC) was computed. A second plasma glibenclamide profile was obtained 2-4 weeks after withdrawal of trimethoprim-sulphamethoxazole. The levels of plasma glibenclamide did not differ between the two occasions, nor did the simultaneously determined levels of blood glucose and plasma insulin. It is concluded that there is no consistent pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole in NIDDM patients.

Acute Disease↗